Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IQV with free AI briefings, catalyst countdowns, and dilution alerts.

IQV · IQVIA Holdings Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.4B Cash on Hand
CF+ Cash Runway
2.1% Short Interest
$311.89 Analyst Target (18)
Follow IQV by email Get an email when IQV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IQV, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Esomeprazole Magnesium Erosive Esophagitis Phase 3 · NCT05267613 Completed
Medi-546 Systemic Lupus Erythematosus Phase 3 · NCT04877691 Active not recruiting
GSK3511294 (Depemokimab) Asthma Phase 3 · NCT04718389 Completed
Olorofim Invasive Aspergillosis Phase 3 · NCT05101187 Completed
Oregovomab Carcinoma, Ovarian Epithelial Phase 3 · NCT04498117 Active not recruiting
Liposomal Amphotericin B Invasive Aspergillosis Phase 3 · NCT05101187 Completed
J147 Emulsion for Injection Acute Ischemic Stroke Phase 2 · NCT07430917 Recruiting
NOC-110 Refractory or Unexplained Chronic Cough Phase 2 · NCT06504446 Active not recruiting
OG-6219 Endometriosis Phase 2 · NCT05560646 Completed
Bedaquiline Drug Susceptible Pulmonary Tuberculosis Phase 2 · NCT07525427 Recruiting
Efgartigimod Primary Sjögren's Syndrome Phase 2 · NCT06203457 Completed
TBD11 (300 mg) Healthy Adult Participants Phase 1 · NCT07883226 Recruiting
Anti-CD137 Agonistic Monoclonal Antibody CTX-471 Locally Advanced Solid Tumor Phase 1 · NCT03881488 Terminated
Talabostat Mesylate Cancer of Pancreas Early Phase 1 · NCT04123574 Withdrawn
Out-of-specification obecabtagene autoleucel Lymphoblastic Leukemia, Acute, Adult N/A · NCT06799221 Available
Non-orexin receptor antagonist medications for… Insomnia N/A · NCT06498128 Terminated

Also used in these trials (approved or third-party drugs, not IQV's own candidates): Pegcetacoplan, Benralizumab, Acellular Tissue Engineered Vessel, Mepolizumab, Nirsevimab, Carboplatin, Paclitaxel, Durvalumab (MEDI4736), Olaparib, Futibatinib, Amivantamab, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IQV holds $2.4B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IQV files for a raise →

👥 Who Owns IQV

Insiders 0.9% Institutions (1673 holders) 99.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 14,433,297 8.76% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 12,714,783 7.72% 2026-03-31
Harris Associates L.P. Institution (13F) 10,442,270 6.34% 2026-09-30
State Street Corporation Institution (13F) 7,516,498 4.56% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 7,362,427 4.47% 2026-09-30
Geode Capital Management, LLC Institution (13F) 4,425,490 2.69% 2026-09-30
Boston Partners Institution (13F) 4,368,759 2.65% 2026-09-30
JPMORGAN CHASE & CO Institution (13F) 4,316,639 2.62% 2026-09-30
Artisan Partners Limited Partnership Institution (13F) 3,461,373 2.10% 2026-09-30
Invesco Ltd. Institution (13F) 2,943,236 1.79% 2026-09-30
Ari Bousbib
Chairman, Chief Executive Officer & Pres · +78,264 options
Insider 1,379,243 0.84% 2026-07-29
John G Danhakl
Director · +3,423 options
Insider 31,887 0.02% 2026-04-23

Share count 164,800,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-09
filed 2026-11-12
Sherbet Eric
Option exercise (M) 8,436 $131.82 29,435
2026-11-09
filed 2026-11-12
Sherbet Eric
Sale (S) 4,446 $278.83 24,989
2026-11-09
filed 2026-11-12
Sherbet Eric
Returned to issuer (D) 3,990 $278.74 20,999
2026-11-09
filed 2026-11-12
Sherbet Eric
Option exercise (M) 8,436 $131.82 –
2026-11-05
filed 2026-11-09
DANHAKL JOHN G
Option award (A) 134 $264.88 –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IQV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IQV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.